²⁰¹Tl⁺-labelled Prussian blue nanoparticles as contrast agents for SPECT scintigraphy

Abstract

Prussian blue (PB) and its analogues on the nanometric scale are exciting nano-objects that combine the advantages of molecular-based materials and nanochemistry. Herein, we demonstrate that ultra-small PB nanoparticles of 2-3 nm can be easily labelled with radioactive (201)Tl(+) to obtain new nanoprobes as radiotracers for 201-thallium-based imaging.

Fashioning Prussian Blue Nanoparticles by Adsorption of Luminophores: Synthesis, Properties, and in Vitro Imaging

“…Moreover, they benefit from an excellent biocompatibility since the so-called “insoluble” form of the bulk PB has been approved by the Food and Drug Administration (FDA) as an antidote for radioactive Cs + and nonradioactive Tl + poisoning . Consequently, the efficiency of nanosized PB has been demonstrated for a myriad of biomedical applications including magnetic resonance imaging (MRI), scintigraphy, photoacoustic imaging, or therapy through different kinds of treatment together with drug delivery , and photothermal therapy . On the other hand, fluorescence imaging is an affordable technique that benefits from a high temporal resolution and high sensitivity .…”

Facile synthesis of magnetic core–shell nanocomposites for MRI and CT bimodal imaging

“…In recent years magnetic resonance imaging (MRI), 1 computed tomography (CT), 2 single-photon emission computed tomography (SPECT), 3 photoacoustic tomography (PAT), 4 and ultrasound (US) imaging 5 have become indispensable clinical methods for diagnosing various diseases. However, a single imaging modality is rarely sufficient to obtain all the necessary information independently.…”

Fluorescent, Prussian Blue-Based Biocompatible Nanoparticle System for Multimodal Imaging Contrast

“…This property is the main reason PB is featured on the World Health Organization (WHO) Model List of Essential Medicines, as the specific category “Antidotes and other substances used in poisoning” PB has been approved for medical use in the United States (US) and in Europe for the abovementioned indication since 2003 [ 10 , 19 ]. Previous studies also described Prussian blue nanoparticles (PBNPs) as potential photothermal therapeutic agents [ 16 ], a promising candidate for different types of imaging [ 20 ], e.g., magnetic resonance-imaging (MRI) (as a T1 and T2 contrast agent) [ 12 , 21 ], optical imaging, and computed tomography [ 22 ]. The most widely used imaging modalities for follow-up studies are MRI and optical imaging (OI).…”

“…Previous studies prove that PBNPs could possibly act as zeolitic and porous structures, absorbing metallic cations and gases in their pores, although the exact binding mechanisms were not fully described and published [ 12 , 13 , 14 ]. It was also previously reported that PBNPs could have a great potential as multimodal contrast agents as well as potential drugs for photodynamic therapy [ 7 , 13 , 15 , 16 ]. Equipped with a suitable biocompatible citrate layer would help to stabilize the particles and render them capable to form surface dendrimers when polyethylene glycols are added to the PBNP solution [ 7 , 12 ].…”